Looking ahead to 25, the Jefferies analyst wrote, catalysts for growth include increasing approvals by state Medicaid programs of the companys tests, ongoing progress on improving its marginsand notably, the onboarding of healthcare institutions to Epic Systems Aura suite of specialty diagnostics
Johnson, M.B., & Brown, L.K
doi: 10.3390/jcm12041454
2021), 2 PhRMA, Research and Development Policy Framework (Sept
However, providers experienced with GLP-1 therapy deliver better outcomes through appropriate dose titration and side-effect management
Apart from the local adverse effects of these agents, the important limitation is the localization of their effect to the site of application alone